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Inge I Bouwman1*†, Boudewijn J Kollen1†, Klaas van der Meer1, Rien JM Nijman2 and Wouter K van der Heide1†Abstract
Background: Although lower urinary tract symptoms (LUTS) seem to be related to cardiovascular disease (CVD) in
men, it is unclear whether this relationship is unbiased. In order to investigate this relationship, we used
longitudinal data for establishing the possible predictive value of LUTS for the development of CVD in a primary
care population.
Methods: We performed a registry study using data from the Registration Network Groningen (RNG). All data from
men aged 50 years and older during the study period from 1 January 1998 up to 31 December 2008 were
collected. Cox proportional hazard regression analysis was used to determine the association between the
proportions of CVD (outcome) and LUTS in our population.
Results: Data from 6614 men were analysed. The prevalence of LUTS increased from 92/1000 personyears (py) in
1998 up to 183/1000 py in 2008. For cardiovascular diseases the prevalence increased from 176/1000 py in 1998 up
to 340/1000 py in 2008. The incidence numbers were resp. 10.2/1000 py (1998) and 5.1/1000 py (2008) for LUTS, and
12.9/1000 py (1998) and 10.4/1000 py (2008) for CVD. Of all men, 23.2% reported CVD (41.1% in men with LUTS vs
19.5% in men without LUTS, p < 0.01). The hazard ratio of LUTS for cardiovascular events, compared to no LUTS, in
the adjusted multivariate model, was 0.921(95% CI: 0.824 - 1.030; p = 0.150).
Conclusion: Based on the results, LUTS is not a factor that must be taken into account for the early detection of
CVD in primary care.Background
Cardiovascular diseases (CVD) are a major cause of mor-
bidity and mortality. Worldwide, CVD is responsible for an
estimated 35 million deaths each year [1,2].
The recently published guidelines ‘Prevention of cardio-
metabolic diseases’ [3] urge general practitioners (GPs)
to play a proactive role in secondary prevention of their
patients at risk, and to manage subsequent intervention
[3,4]. Identifying associated morbidities that may precede
CVD could assist the GP in this role.
Research in the past decade has revealed an association
between CVD and erectile dysfunction (ED) in community
based and clinical studies [5-7]. The incidence of coronary* Correspondence: iibouwman@hotmail.com
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reproduction in any medium, provided the orheart diseases in Dutch men, in 2007, increases from
5/1000 men aged 50 up to 30/1000 men aged 80 [3].
The incidence of ED in general practice is, however, low
(1.7/1000 men/year) [8]; using ED to help identify patients
at risk for CVDs will not improve the efficacy of prevention
activities. On the other hand ED is also associated with
Lower Urinary Tract Symptoms (LUTS) in both commu-
nity and clinically based populations [9-13]. The incidence
of LUTS in the general practice population increases with
age, from 2.2 in men aged < 45 years up to 18.7/1000
patients/year for men aged 85 years and older [14-16].
For the GP, it is therefore a more useful instrument in
case finding of individuals with CVD than ED (incidence in
primary care population: 1.7/1000 patients/year, increasing
up to 5.6/1000 patients/year for men aged 65–74 years [8]).
A few clinical studies have reported a cross-sectional
relationship between LUTS and CVD [17-26]. Also, in
one community based longitudinal study, a longitudinaltral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Definitions of study parameters and ICPC codes
Study parameter ICPC code and definition
Lower urinary tract
symptoms
U02: frequency, U05: other voiding symptoms,
U07: other symptoms, U13: other symptoms
bladder, U29: other symptoms urinary tract,
Y06: symptoms prostate, Y85: benign prostate
hypertrophy
Erectile dysfunction Y07: symptoms sexual potential
Cardiovascular
diseases
K74: angina pectoris, K75: acute myocardial
infarction, K76: other chronic ischaemic heart




K86: hypertension without organ damage, K87:
hypertension with organ damage, T82 obesity
Quetelet Index > 30, T83: obesity QI < 30, P17:
smoking, P15: chronic alcohol abuse, T93:
dislilpydemia




Antidiabetics: oral and insulin therapy
Antihypertensives: ACE inhibitors, AII receptor
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However, the relationship between LUTS and CVD has
not yet been demonstrated in a primary care setting.
LUTS and CVD share some risk factors such as obesity,
diabetes, hypertension, smoking, and ageing [23,24]. The
underlying pathophysiological relationship could be ex-
plained by fluid shifts, hormonal and autonomic nervous
disturbances caused by hypertension and heart failure, but
also by waking due to nycturia [17-26]. Endothelial dys-
function in the pelvic vascular system might contribute
to bladder dysfunction with rising age [5]. Also, diabetes
mellitus can lead to LUTS via neurogenic bladder dysfunc-
tion with detrusor underactivity [5].
The hypothesis that LUTS could be associated with the
development of CVD still needs to be confirmed in pri-
mary care. The only evidence to date is one longitudinal,
community-based study conducted on a small group of
men with severe LUTS [25]. Therefore, the objective of our
study is to explore the relationship between LUTS and
CVD in a primary care population.
Methods
We performed a registry study using data from the
Registration Network Groningen (RNG), one of several
registration networks in the Netherlands. These registration
networks carry out research on data derived from the elec-
tronic registration of daily patient care in their participating
general practices. The Registration Network Groningen
was established in 1989, and has three practices in the
north of the Netherlands, with an annual population of
approximately 30,000 patients [27].
In the Netherlands, the GP is the gatekeeper in the Dutch
health-care system controlling access to specialized medical
care. Virtually all non-institutionalized Dutch citizens
are registered with a GP so the total practice population
represents the general population [28].
GPs working in the RNG-practices use a structured med-
ical record, in which all patient contacts are registered. This
includes reason for encounter, medical diagnosis (according
to the International Classification of Primary Care (ICPC)
[29]), applied treatment (among which prescriptions, using
the Anatomical Therapeutic Chemical (ATC) codes [30],
and referrals), but also cause of death. The database also
includes population dynamics, such as date of entry and
departure from the database.
From the RNG registration, we selected all data from
men aged 50 years and older (age at any time during the
study period: 1January 1998–31 December 2008).
Patients with a history of Prostate Cancer, as well as
men with a history of CVD were excluded for longitudinal
analysis. Access to the patient’s medical history was a
prerequisite. We collected the following data from the
registration: date of birth, date of entry in the study, date
of and reason for leaving the registration, GP code, patientcontacts (ICPC codes), prescriptions (ATC codes) and
ICPC codes attached to these medications, and hospital
referrals. From this information, we calculated age from
date of birth and number of person years in study. All of
the data were anonymised. We received ethical permission
to access the Registration Network Groningen from
the Medical Ethical Research Board, University Medical
Center Groningen (M13.132482).
Definitions
Cardiovascular event is defined as a documented acute
myocardial infarction, chronic ischaemic heart disease,
transient ischemic attack or stroke in the medical records
of the GPs [31]. Table 1 provides the ICPC codes as regis-
tered by the RNG-GPs that were used for this study and
recode this according to the ICPC. For each participant,
we defined CVD-status at baseline (01-01-1998), or at date
of study entry, as being present (previous cardiovascular
event before inclusion in the study) or absent.
Lower urinary tract symptoms (LUTS) include the sen-
sation of not urinating completely, withholding urinating,
and difficulty voiding. This may include having a stop-
and-go urinary flow and getting up frequently at night
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therefore we defined LUTS by all relevant ICPC codes or
use of LUTS medication (Table 1).
Erectile dysfunction is defined as the persistent inability
to achieve or maintain an erection suficient for satisfactory
sexual performance [33], in this study defined by the ICPC
code Y07: symptoms sexual potential.
Statistical analysis
Descriptive statistics were used to compare the baseline
characteristics. Continuous variables are presented in
means and confidence intervals, and nominal variables
reported in modi. Prevalences (and incidence numbers for
LUTS and CVD) for LUTS, CVD, hypertension, Erectile
dysfunction, and Diabetes mellitus were calculated by
means of prevalence/1000 personyears for the first and
last studyyear (1998 and 2008).
Cox proportional hazard regression analysis was used
to determine the association between the proportions of
CVD (outcome) and LUTS in our population. We used age
as time factor in a Cox proportional hazard regression ana-
lysis to determine the association between CVD (outcome)
and LUTS in our population. In this open cohort, time to
event (CVD) was calculated from the patient’s date of birth
to event (i.e. diagnosis of LUTS) and data of subjects were
censored in case leaving the cohort, death, or end of study.
Initially, an unadjusted analysis was performed. This as-
sociation regression model was subsequently corrected for
confounders. A covariate was considered a confounder in
the event the beta coefficient of LUTS changed by 10 or
more percent [34].
In this analysis, the following potential confounders
[35] were tested: hypertension, diabetes mellitus, obesity,
dyslipidaemia, depression, and antihypertensive (ACE-in-
hibitors, all antagonists, beta blockers, calcium antagonists,
and diuretics), and statins.
In all analyses, multiple dummy variables were created
for the analyses of categorical data. In addition, model
assumptions were tested for compliance. All analyses were




From the database, we collected data from 6614 eligible
men. Of these, 1165 (17.6%) reported LUTS during the
study period. Table 2 describes the patient characteristics,
for the total sample, and for men with and without LUTS.
The prevalence of LUTS increased from 92/1000 person-
years (py) in 1998 up to 183/1000 py in 2008. The incidence
numbers of LUTS were 10.2/1000 py in 1998 and 5.1/
1000 py in 2008.
From all men, 1539 had cardiovascular diseases during
the study period: 23.2% (95% CI 22.2-24.2%) (41.1% inmen with LUTS vs 19.5% in men without LUTS, p < 0.01).
The incidence numbers for CVD were 12.9/1000 py in
1998 and 10.4/1000 py in 2008.
Table 3 shows the outcome of LUTS and CVD by
agegroups among the study population. Both LUTS and
CVD are more prevalent in the highest age group. The
prevalence of CVD increased from 176/1000 py in 1998
up to 341/1000 py in 2008. From all men 26.5% had
hypertension, significantly more prevalent in the LUTS
group (40.2% in men with LUTS vs. 23.5% in men without
LUTS, p < 0.01). The prevalence of hypertension increased
during the study period, from 206/1000 py in 1998 up to
387/1000 py in 2008. Also Erectile Dysfunction was more
prevalent in the LUTS group (2.8% in men with LUTS vs.
1.0% in men without LUTS, p < 0.01). The prevalence of
ED increased from 17/1000 py in 1998 up to 19/1000 py
in 2008 during the period 1998–2008. Diabetes mellitus
was prevalent in 5.7% of all men, the prevalence increased
from 24/1000 py in 1998 up to 82/1000 py in 2008. The
prevalence of DM was not significantly (p = 0.85) different
in the LUTS group compared to the non-LUTS group.
Dyslipidemia was prevalent in 20.4% of all patients. It was
significant more prevalent in the LUTS group (p 0.005)
than in the non LUTS group. The prevalences of lifestyle
factors as obesity, smoking, alcohol abuse were 3.9, 13.4,
and 3.8% respectively. There were no significant differences
between the LUTS and non-LUTS group for lifestyle fac-
tors (p-values are 0.42, 0.52, and 0.18 respectively).
Longitudinal analysis
There is a significant unadjusted univariate relationship
between the proportions cardiovascular events and LUTS
(HR 1.16, 95% CI: 1.035 - 1.291; p = 0.010). However, the
hazard ratio of LUTS for cardiovascular events, compared
to no LUTS, in the adjusted multivariate model, was non-
significant (HR = 0.921, 95% CI: 0.824 - 1.030; p = 0.150).
Therefore, men with LUTS were not more likely to develop
CVD, at any time, than men without LUTS. In our analysis,
hypertension, ACE-inhibitors, All antagonists, beta blockers,
and calcium antagonists were found to confound this
relationship. In this population, cardiovascular disease was
not associated with LUTS (Table 4).
Discussion
Main findings
Nowadays, when a patient consults his general practitioner
for LUTS, it is not customary to search for comorbidities
such as CVD. However Dynamic cohort and clinical studies
suggest a correlation between LUTS and CVD. To the best
of our knowledge this is the first study that has been done
to establish the relationship between LUTS and CVD in a
primary care population. This is an important population
because the GP plays an increasingly prominent role
with respect to the early detection of patients at risk, for
Table 2 Population characteristics
Characteristics All men
(n = 6614) (%)
Men without LUTS
(n = 5449) (82.4%)
Men with LUTS
(n = 1165) (17.6%)
p-value
Age, mean (SD), y 56 (12) 54 (11) 65 (12)
Report of cardiovascular disease (*1) 1539(23.2) 1060(19.5) 479(41.1) 0.000*
Report of hypertension (K86 + K87) 1751(26.5) 1283(23.5) 468(40.2) 0.000*
Report of erectile dysfunction (*2) 89(1.3) 56(1.0) 33(2.8) 0.000*
Report of diabetes mellitus (T90) 368(5.7) 286(5.2) 92(7.9) 0.000*
Report of obesity 260(3.9) 204(3.7) 56(4.8) 0.090
Report of current smoking 884(13.4) 751(13.8) 133(11.4) 0.031*
Report of alcohol abuse 254(3.8) 230(4.2) 24(2.1) 0.000*
Report of dislipydemia 1350(20.4) 1046(19.2) 304(26.1) 0.000*
Use of LUTS medication (*3) 7242(10.9) 5(0.1) 717(61.5) 0.000*
Use of DM medication (*4) 29(0.4) 22(0.4) 7(0.6) 0.355
Use of antihypertensives
Use of aII antagonist 412(6.0) 256(4.7) 156(13) 0.000*
Use of ACE inhibitors 1278(19.3) 937(17.2) 341(29.3) 0.000*
Use of beta blockers 1787(27.0) 1327(24.4) 460(39.5) 0.000*
Use of calcium antagonists 867(13.1) 579(10.6) 288(24.7) 0.000*
Use of diuretics 1063(16.1) 732(13.4) 331(28.4) 0.000*
Use of statins 1145(17.3) 879(16.1) 266(22.8) 0.035*
Use of ED medication 389(5.9) 282(5.1) 107(9.1) 0.010*
Data are expressed as No. (%) unless otherwise noted. SD: standard deviation, y: year. *1: Cardiovascular Diseases include K74 (angina pectoris), K75 (acute
myocardial infarction), K76 (other chronic ischaemic heart diseases), K89 (TIA), and K90 (CVA). *2: Erectile Dysfunction includes: Y07 (symptoms sexual potential),
*3: Use of medication for Lower Urinary tract symptoms, *4: Use of medication for Diabetes mellitus.
*: p-value significant (<0.05).
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we investigated 1165 men with LUTS. Based on the results,
LUTS is not a factor that must be taken into account for
the detection of CVD, in primary care.
Interpretation of findings in relation to previously
published work
Other studies report the association between LUTS and
CVD [17,18,36]. The results suggest that vascular riskTable 3 CVD status by age and LUTS status among the study
No LUTS, n = 5449
N (% within presence of LUTS)




50–54 yrs 3015 (90.7) 309 (9.3) 3324 (61.0) 223
55-59 yrs 509 (77.5) 148 (22.5) 657 (12.1) 92 (6
60-64 yrs 333 (72.1) 129 (27.9) 462 (8.5) 82 (5
65-69 yrs 215 (57.8) 157 (42.2) 372 (6.8) 86 (4
70-78 yrs 317 (50) 317 (50) 634 (11.6) 203
All ages 4389 (80.5) 1060 (19.5) 5449 (100%) 686
LUTS: Lower Urinary Tract Symptoms, CVD: cardiovascular disease.factors seem to be associated with the presence and degree
of LUTS, prostate size or outflow obstruction. Vascular
diseases such as atherosclerosis and endothelial dysfunc-
tion in the pelvic vascular system are one of the possible
mechanisms contributing to bladder dysfunction with age
[17]. Increased sympathetic activity and/or a1-adrenorecep-
tor activity might be a common pathway for both hyperten-
sion and LUTS, and might explain the improvement in
LUTS with the use of a1- adrenoreceptor antagonist [36].population
LUTS, n = 1165






(85.1) 39 (14.9) 262 (22.5) 348 (22.6) 0.003
6.2) 47 (33.8) 139 (11.9) 159 (10.3) 0.005
7.3) 61 (42.7) 143 (12.3) 190 (12.3) 0.001
9.9) 88 (50.6) 174 (14.9) 245 (15.9) 0.067
(45.4) 244 (45.4) 447 (38.4) 561 (36.5) 0.137
(58.9) 479 (41.1) 1165 (100%) 1539 (100%) 0.000
Table 4 The association between LUTS and CVD from
longitudinal analyses, final model
Outcome Unadjusted Multivariate adjusted *
HR (95% CI, p-value) HR (95% CI, p-value)
CVD 1.16 (1.035 - 1.291, p 0.010) 0.921 (0.824-1.030, p 0.150)
*Variables in multivariate analysis: Hypertension, ACE inhibitors, AII antagonists,
beta blockers, Calcium antagonists.
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factors were 3 times more likely to have moderate/severe
LUTS than men without vascular risk factors (OR 3.6
(95% CI 1.19-10.62, p0.024). However, these studies are
mostly clinical studies [17-22]. There are often considerable
methodological and population differences between them.
This latter is an important point as we cannot generalise
the results from other studies (all clinical- or community
based studies) to the patient population of the GP. Also the
cross-sectional setting of the studies makes them not
suitable to analyse causal relationships.
Recently, a community-based retrospective, cross-sectional
and longitudinal study into this relationship was carried
out [25]. Wehrberger et al. concluded that men with se-
vere LUTS have an increased risk of developing
CVD. They investigated a large group of people with LUTS
(n = 2092). However, the conclusions of their study were
based on just 1% of the total study population. Another
population based longitudinal study did not found an
association between LUTS and CVD, but was especially
focussed on nycturia as a subcategory of LUTS [37].
Strengths and limitations
The strength of our study is the longitudinal analysis, and
the large cohort of 6615 men. Using data from electronic
medical records from general practices makes it possible
to compare the prevalence of CVD between different
patient groups in the same study population. We also
had information about the sequence of the diseases, LUTS
and CVD events, and hence a possible relationship between
LUTS and subsequent CVD could be taken into the statis-
tical analyses.
According to previous articles about RNG data, this
study population is representative for the Dutch popu-
lation [38].
A limitation of this study is having access to large patient
populations in a health registry with data that are not
collected in a structural way. Patients are not measured
periodically. Important confounders, such as dyslipidemia,
smoking and obesity, are not always registered in the elec-
tronical medical records of GPs. For example, in this study
dyslipidemia is more frequent in men with LUTS. However,
the prevalence of dyslipidemia in all subjects is lower than
the Dutch prevalence numbers [39]. Because we cannot
exclude underregistration of cardiovascular risk factors,
we chose not to draw any conclusions from this finding.An additional investigation into medical files could yield
some of the unknown information about cardiovascular
risk factors, in a longitudinal study-setting.
Because of the absence of an ICPC code for LUTS, we
assumed the presence of LUTS if one or more of these
ICPC codes were identified (Table 1). Unfortunately, this
did not always agree with the LUTS definition from other
studies. As we did not measure the International Prostate
Symptom Score (IPSS) of men with LUTS, we were unable
differentiate between men with mild, moderate or severe
LUTS.
Another factor that should be considered is the under-
reporting of LUTS, the so-called iceberg phenomenon:
[15,40,41] i.e. the reported incidence and population
prevalence differ considerably (contact with GP for LUTS:
from 4-9% up to 23%) [15,42]. Consequently, fewer LUTS
cases are identified by the GP than are actually present in
the practice population. The lack of relationship established
between LUTS and CVD might therefore be incorrect.
Conclusions
To the best of our knowledge, this is the first study that
investigated the relationship between LUTS and cardiovas-
cular diseases in primary care. It suggests that a GP does
not have to complete a full cardiac risk profile in men
who present with LUTS symptoms for the first time.
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